Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: systemic outcomes from a randomized trial

Published: 24 February 2025| Version 1 | DOI: 10.17632/yzv3mrvwf4.1
Contributors:
Zhenyu Zhong, Jiayi Wang, Weiting Liao, Junjie Xiang, Tao Cai, Peizeng Yang

Description

Vogt-Koyanagi-Harada (VKH) disease causes vitiligo, poliosis, and alopecia.We aim to investigate the effect of prednisone plus either adalimumab or cyclosporine-based immunosuppression on VKH dermatological disorders using ancillary data from a VKH eye disease trial. The data shows detailed outcomes including changes in vitiligo, poliosis, alopecia, headache, meningismus, tinnitus and dysacusis in the trial. Overall, there was a decrease in the percentage of alopecia but no change in the presence of vitiligo or poliosis at month 6. The adalimumab group showed no nominally significant differences in the percentage changes of each dermatological manifestation but a greater reduction in the number of affected dermatological categories compared with the cyclosporine group.

Files

Categories

Dermatology, Vogt-Harada-Konishi Syndrome

Licence